Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis

被引：6

作者：

Inada, Kento ^{[1
]}

Kaneko, Shun ^{[1
]}

Kurosaki, Masayuki ^{[1
]}

Yamashita, Koji ^{[1
]}

Kirino, Sakura ^{[1
]}

Osawa, Leona ^{[1
]}

Hayakawa, Yuka ^{[1
]}

Sekiguchi, Shuhei ^{[1
]}

Higuchi, Mayu ^{[1
]}

Takaura, Kenta ^{[1
]}

Maeyashiki, Chiaki ^{[1
]}

Tamaki, Nobuharu ^{[1
]}

Yasui, Yutaka ^{[1
]}

Itakura, Jun ^{[1
]}

Takahashi, Yuka ^{[1
]}

Tsuchiya, Kaoru ^{[1
]}

Nakanishi, Hiroyuki ^{[1
]}

Okamoto, Ryuichi ^{[2
]}

Izumi, Namiki ^{[1
]}

机构：

[1] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, 1-26-1 Kyonan Cho, Musashino, Tokyo 1808610, Japan

[2] Tokyo Med & Dent Univ, Dept Gastroenterol & Hepatol, Tokyo, Japan

来源：

JGH OPEN | 2021年 / 5卷 / 09期

关键词：

de novo hepatitis; hepatitis B virus reactivation; tenofovir alafenamide; CYTOTOXIC CHEMOTHERAPY; DISOPROXIL FUMARATE; MANAGEMENT; INFECTION; THERAPY;

D O I：

10.1002/jgh3.12636

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background and Aim: Administration of tenofovir alafenamide (TAF) as prevention or treatment of hepatitis B virus (HBV) reactivation is not well known. The aim of this study is to reveal the efficacy and safety of TAF against HBV reactivation. Methods: Entecavir (ETV) and TAF were given to 66 and 11 patients, respectively, as prophylaxis against or treatment of HBV reactivation during chemotherapy or immune suppression therapy from January 2010 to June 2020. The antiviral effects and safety were assessed. Results: At week 24, the antiviral effects on patients receiving ETV and TAF were similar in terms of reduction of HBV DNA (-2.83 +/- 1.45log IU/mL vs -3.05 +/- 2.47log IU/mL; P = 0.857) and achieving undetectable levels of HBV DNA (78.8 vs 90.9%; P = 0.681). There was no significant difference in the decrease in the estimated glomerular filtration rate (eGFR) between the two groups (-0.62 +/- 11.2 mL/min/1.73 m(2) vs -3.67 +/- 13.2 mL/min/1.73 m(2); P = 0.291). Conclusion: TAF is safe and effective against HBV reactivation.

引用

页码：1085 / 1091

页数：7

共 28 条

[21] Terrault Norah A, 2018, Hepatology, V67, P1560, DOI [10.1002/cld.728, 10.1002/hep.29800]
[22] Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada
Tian, Feng
Houle, Sherilyn K. D.
Alsabbagh, Mhd. Wasem
Wong, William W. L.
[J]. PHARMACOECONOMICS, 2020, 38 (02) : 181 - 192
[23] Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation
Toka, Bilal
Koksal, Aydin Seref
Eminler, Ahmet Tarik
Tozlu, Mukaddes
Uslan, Mustafa Ihsan
Parlak, Erkan
[J]. DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (07) : 2417 - 2426
[24] Yeo W, 2000, J MED VIROL, V62, P299, DOI 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO
[25] 2-0
[26] Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation
Zhang, Min-Yue
Zhu, Gui-Qi
Shi, Ke-Qing
Zheng, Ji-Na
Cheng, Zhang
Zou, Zhuo-Lin
Huang, Hong-Hui
Chen, Fang-Yuan
Zheng, Ming-Hua
[J]. ONCOTARGET, 2016, 7 (21) : 30661 - 30677
[27] Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
Zhang, Xuanye
Zhou, Yixin
Chen, Chen
Fang, Wenfeng
Cai, Xiuyu
Zhang, Xiaoshi
Zhao, Ming
Zhang, Bei
Jiang, Wenqi
Lin, Zuan
Ma, Yuxiang
Yang, Yunpeng
Huang, Yan
Zhao, Hongyun
Xu, Ruihua
Hong, Shaodong
Zhang, Li
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
[28] Hepatitis B virus resistance to antiviral drugs: where are we going?
Zoulim, Fabien
[J]. LIVER INTERNATIONAL, 2011, 31 : 111 - 116

← 1 2 3 →